Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thor-Henrik Brodtkorb

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Pharmacoeconomics - Open|March 29, 2020
The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque PsoriasisJustin Carrico, Yang Zhao, Xiaoying Jia, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|February 26, 2014
Relationship between modeling technique and reported outcomes: case studies in models for the treatment of schizophreniaBirgitta von Schéele, Josephine Mauskopf, Thor-Henrik Brodtkorb, et al.
Journal of Medical Economics|February 22, 2024
Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placeboSiguroli Teitsson, Thor-Henrik Brodtkorb, Murat Kurt, et al.
Oncology and Therapy|November 15, 2025
Cost-effectiveness of Nivolumab + Platinum Doublet Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer in EnglandJoel Russell, Mack Harris, Ariel Sun, et al.
Health and Quality of Life Outcomes|March 19, 2021
Health state utility values in major depressive disorder treated with pharmacological interventions: a systematic literature reviewJames Brockbank, Taryn Krause, Emily Moss, et al.
Journal of Medical Economics|March 12, 2024
Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspectiveThor-Henrik Brodtkorb, Christopher Knight, Farzam Kamgar, et al.
BMJ Open|September 18, 2014
The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov modelPhilippe Laramée, Thor-Henrik Brodtkorb, Nora Rahhali, et al.
Clinical Drug Investigation|July 30, 2016
A Comparison of Markov and Discrete-Time Microsimulation Approaches: Simulating the Avoidance of Alcohol-Attributable Harmful Events from Reduction of Alcohol Consumption Through Treatment of Alcohol DependencePhilippe Laramée, Aurélie Millier, Thor-Henrik Brodtkorb, et al.
The Journal of Dermatological Treatment|April 3, 2020
Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasisJashin J Wu, Xiaoying Jia, Yang Zhao, et al.
The Journal of Dermatological Treatment|July 1, 2020
Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United StatesXiaoying Jia, Yang Zhao, Justin Carrico, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Pharmacoeconomics - Open|March 29, 2020
The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque PsoriasisJustin Carrico, Yang Zhao, Xiaoying Jia, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|February 26, 2014
Relationship between modeling technique and reported outcomes: case studies in models for the treatment of schizophreniaBirgitta von Schéele, Josephine Mauskopf, Thor-Henrik Brodtkorb, et al.
Journal of Medical Economics|February 22, 2024
Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placeboSiguroli Teitsson, Thor-Henrik Brodtkorb, Murat Kurt, et al.
Oncology and Therapy|November 15, 2025
Cost-effectiveness of Nivolumab + Platinum Doublet Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer in EnglandJoel Russell, Mack Harris, Ariel Sun, et al.
Health and Quality of Life Outcomes|March 19, 2021
Health state utility values in major depressive disorder treated with pharmacological interventions: a systematic literature reviewJames Brockbank, Taryn Krause, Emily Moss, et al.
Journal of Medical Economics|March 12, 2024
Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspectiveThor-Henrik Brodtkorb, Christopher Knight, Farzam Kamgar, et al.
BMJ Open|September 18, 2014
The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov modelPhilippe Laramée, Thor-Henrik Brodtkorb, Nora Rahhali, et al.
Clinical Drug Investigation|July 30, 2016
A Comparison of Markov and Discrete-Time Microsimulation Approaches: Simulating the Avoidance of Alcohol-Attributable Harmful Events from Reduction of Alcohol Consumption Through Treatment of Alcohol DependencePhilippe Laramée, Aurélie Millier, Thor-Henrik Brodtkorb, et al.
The Journal of Dermatological Treatment|April 3, 2020
Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasisJashin J Wu, Xiaoying Jia, Yang Zhao, et al.
The Journal of Dermatological Treatment|July 1, 2020
Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United StatesXiaoying Jia, Yang Zhao, Justin Carrico, et al.
Pageof 2